Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

For an accessible version of this Press Release, please visit www. tevapharm. com Q1 2026 revenues of ~$4. 0 billion increased by 2% in U. S.